These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 30745277)
1. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials. White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277 [TBL] [Abstract][Full Text] [Related]
2. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali. Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687 [TBL] [Abstract][Full Text] [Related]
3. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso. Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686 [TBL] [Abstract][Full Text] [Related]
4. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years. Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684 [TBL] [Abstract][Full Text] [Related]
5. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign? Yaro S; Njanpop Lafourcade BM; Ouangraoua S; Ouoba A; Kpoda H; Findlow H; Tall H; Seanehia J; Martin C; Ouedraogo JB; Gessner B; Meda N; Borrow R; Trotter C; Mueller JE Clin Infect Dis; 2019 Jan; 68(3):435-443. PubMed ID: 30481265 [TBL] [Abstract][Full Text] [Related]
6. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines. Idoko OT; Okolo SN; Plikaytis B; Akinsola A; Viviani S; Borrow R; Carlone G; Findlow H; Elie C; Kulkarni PS; Preziosi MP; Ota M; Kampmann B Vaccine; 2014 Jul; 32(33):4220-7. PubMed ID: 24863486 [TBL] [Abstract][Full Text] [Related]
7. Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac. Tang Y; Plikaytis BD; Preziosi MP; Borrow R Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S531-9. PubMed ID: 26553685 [TBL] [Abstract][Full Text] [Related]
8. Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays. Price GA; Hollander AM; Plikaytis BD; Mocca BT; Carlone G; Findlow H; Borrow R; Sow SO; Diallo A; Idoko OT; Enwere GC; Elie C; Preziosi MP; Kulkarni PS; Bash MC Clin Infect Dis; 2015 Nov; 61 Suppl 5():S554-62. PubMed ID: 26553688 [TBL] [Abstract][Full Text] [Related]
10. Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age. Tapia MD; Findlow H; Idoko OT; Preziosi MP; Kulkarni PS; Enwere GC; Elie C; Parulekar V; Sow SO; Haidara FC; Diallo F; Doumbia M; Akinsola AK; Adegbola RA; Kampmann B; Chaumont J; Martellet L; Marchetti E; Viviani S; Tang Y; Plikaytis BD; LaForce FM; Carlone G; Borrow R Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S514-20. PubMed ID: 26553683 [TBL] [Abstract][Full Text] [Related]
11. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers. Bash MC; Lynn F; Mocca B; Borrow R; Findlow H; Hassan-King M; Preziosi MP; Idoko O; Sow S; Kulkarni P; Laforce FM Clin Vaccine Immunol; 2014 May; 21(5):755-61. PubMed ID: 24671551 [TBL] [Abstract][Full Text] [Related]
12. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323 [TBL] [Abstract][Full Text] [Related]
13. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711 [TBL] [Abstract][Full Text] [Related]
15. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Findlow H; Plikaytis BD; Aase A; Bash MC; Chadha H; Elie C; Laher G; Martinez J; Herstad T; Newton E; Viviani S; Papaspyridis C; Kulkarni P; Wilding M; Preziosi MP; Marchetti E; Hassan-King M; La Force FM; Carlone G; Borrow R Clin Vaccine Immunol; 2009 Jul; 16(7):969-77. PubMed ID: 19474264 [TBL] [Abstract][Full Text] [Related]
16. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization. Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915 [TBL] [Abstract][Full Text] [Related]
17. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Patel M; Lee CK Cochrane Database Syst Rev; 2005 Jan; (1):CD001093. PubMed ID: 15674874 [TBL] [Abstract][Full Text] [Related]
18. Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac®. Trotter CL; Cibrelus L; Fernandez K; Lingani C; Ronveaux O; Stuart JM Vaccine; 2015 Nov; 33(46):6212-7. PubMed ID: 26463444 [TBL] [Abstract][Full Text] [Related]